| |
ADC
|
SqCC
|
|---|
|
n
|
%
|
n
|
%
|
|---|
|
Patients, n
|
627
|
100
|
543
|
100
|
|
General NSCLC markers
|
|
TTF1
|
|
Positivity
|
548
|
87
|
6
|
1
|
|
Negativity
|
79
|
13
|
537
|
99
|
|
p40
|
|
Positivity
|
8
|
1
|
511
|
94
|
|
Negativity
|
619
|
99
|
32
|
6
|
|
Positivity for neuroendocrine marker
|
|
Overalla
|
110
|
18
|
80
|
15
|
|
Synaptophysin
|
84
|
13
|
20
|
4
|
|
Chromogranin A
|
16
|
3
|
4
|
1
|
|
CD56
|
41
|
7
|
3
|
1
|
|
Synaptophysin / Chromogranin A
|
12
|
2
|
1
|
0
|
|
Synaptophysin / CD56
|
19
|
3
|
4
|
1
|
|
Chromogranin A / CD56
|
10
|
2
|
2
|
0
|
|
Synaptophysin / Chromogranin A / CD56
|
10
|
2
|
0
|
0
|
- ADC adenocarcinoma, IHC immunohistochemistry, NSCLC non-small cell lung carcinoma, SqCC squamous cell carcinoma
- aOverall positivity was defined as positivity for ≥1 neuroendocrine marker
